The findings come out of the UH Cancer Center, Hawaiʻi’s only National Cancer Institute-designated cancer center. Based in Kakaʻako, the center directly employs more than 300 faculty and staff and ...

Partnership with Kelun-Biotech expands pipeline and accelerates combination strategy with CR-001, a PD-1 x VEGF bispecific antibody, and multiple antibody-drug conjugates (ADCs), generating clinical ...

New research published in Nature Communications has linked a normal cellular process to an accumulation of DNA mutations in ...

Partnership with Kelun-Biotech expands pipeline and accelerates combination strategy with CR-001, a PD-1 x VEGF bispecific antibody, and multiple ...

Recently, Clinical study results from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (Kelun-Biotech, HKEX: 6990)'s TROP2 ADC sacituzumab tirumotecan (sac-TMT) monotherapy for advanced or metastatic ...

Tubulis’ lead antibody-drug conjugate (ADC) TUB-040 is directed against NaPi2b, an antigen highly overexpressed in ovarian cancer and lung adenocarcinoma. It consists of an IgG1 antibody targeting ...

Second antibody-drug conjugate (ADC) to progress into clinical development utilizing our proprietary payload and optimized antibody Preclinical results demonstrate strong anti-tumor activity and ...

Andrés Aguilera's laboratory, in collaboration with that of Ralf Wellinger (both professors in the Department of Genetics at the University of Seville in CABIMER) and with PharmaMAR, has identified ...